Cardiovascular risk and triptan usage among patients with migraine

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Migraine is a neurovascular disorder linked to a higher risk of ischemic vascular events.
• Triptans, a common migraine treatment, induce vasoconstriction, raising concerns for patients with cardiovascular risks.

Purpose of the Study:

• To investigate the association between triptan usage and cardiovascular (CV) events in migraine patients.
• To assess the safety of triptans in individuals with cardiovascular risk factors.

Main Methods:

• A retrospective, population-based cohort study in southern Israel (2000-2022).
• Analysis of electronic medical records for 26,054 migraine patients, assessing triptan use and CV events within 90 days.
• Sensitivity analyses were performed for varying timeframes and usage patterns.

Main Results:

• 48.2% of patients initiated triptan therapy; CV risk factors were more prevalent in the non-triptan group.
• CV events occurred slightly more in the triptan group (5.1%) vs. non-triptan (4.1%).
• Multivariable analysis showed no significant association between triptan use and increased CV events (aHR 0.96, 95% CI 0.77-1.23).

Conclusions:

• Triptan usage was not associated with an increased risk of cardiovascular events in migraine patients.
• This finding holds true even for patients with existing cardiovascular risk factors.
• Individual risk factor assessment remains crucial for safe triptan prescription.